Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, and Immunotherapy and Immune Responses.
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.
Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037
Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037
Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma